Ucwaningo Oluphumelelayo Luqinisekisa Ukuphepha Nokusebenza Kahle Kokwelashwa Kwe-CD19/CD20 CAR-T Kwe-r/r B-NHL

Ucwaningo olusha olushicilelwe ku- Igaziiqokomisa intuthuko ephumelelayo ye-prizloncabtagene autoleucel (prizlon-cel), ukwelashwa okusha kweseli le-CAR-T eliqondiswe ku-CD19/CD20, lokwelapha iseli le-B eliphinde labuyela emuva/elingasasebenzi kahle. I-Non-Hodgkin Lymphoma (r/r B-NHL). Ukuhlolwa, okuyisifundo sesigaba 1, esisezindaweni eziningi, esivulelekile esenziwa eShayina, kunikeza idatha ethembisayo ngokuphepha kanye nokusebenza kahle kwale ndlela eqondiswe kabili.

Luholwa yithimba labacwaningi abavelele abavela ezikhungweni ezihlanganisa iSibhedlela i-First Affiliated Hospital saseZhejiang University kanye neTongji University, lolu cwaningo lwabhalisa iziguli ezingu-48 ezine-r/r B-NHL, iningi lazo elikhulu. I-B-Cell Lymphoma (LBCL). Iziguli zazike zathola ukwelashwa okuphakathi kwemigqa emithathu. Abahlanganyeli bathole ukumnika okukodwa kwe-prizlon-cel ngemuva kokwelashwa ngamakhemikhali e-lymphodepleting, kanye nemithamo esukela emazingeni amathathu (DL1, DL2, kanye ne-DL3).

Okutholakele Okubalulekile:

• Iphrofayili Yokuphepha: Akukho ubuthi obukhawulela umthamo (i-DLT) obubonwe, futhi ukwelashwa kwabonisa imiphumela emibi elawulekayo. I-Cytokine release syndrome (i-CRS) yenzeka ku-93.8% weziguli, ikakhulukazi ibanga 1-2, kanye necala elilodwa kuphela lebanga 3. I-immunoeffector cell-associated neurotoxicity syndrome (i-ICANS) yayingavamile futhi imnene, ingenazo izehlakalo zebanga 3 noma ngaphezulu.
• Ukusebenza kahle: Izinga lokuphendula lilonke (ORR) elingu-91.5% lifinyelelwe, ngesilinganiso sokuphendula okuphelele (CR) esingu-85.1%. Phakathi kweziguli ezine-LBCL, amazinga e-ORR kanye ne-CR ayengu-90.7% kanye no-86.0%, ngokulandelana. Okuphawulekayo ukuthi ama-48.9% eziguli agcine i-CR ekulandeleni kokugcina, kanti ezinye izimpendulo zidlule iminyaka emithathu.
• Imiphumela Yokusinda: Izilinganiso zikaKaplan-Meier zembule ubude beminyaka emi-2 yokusabela (i-DOR), ukusinda okungenalo inqubekela phambili (i-PFS), kanye namazinga okusinda okuphelele (i-OS) angu-66.0%, 62.6%, kanye no-76.5%, ngokulandelana. Ezigulini ze-CR, la mazinga ayephezulu nakakhulu.

I-Prizlon-cel ibonise ukukhula okuqinile kanye nokuphikelela kwesikhathi eside, ngesikhathi esimaphakathi sokululama kwamaseli e-B esiyizinsuku ezingu-185. Idizayini yayo eqondiswe kabili ibhekana nokuphunyuka kwe-antigen, indlela evamile yokumelana ekwelashweni kwe-CAR-T.